Related Experiment Video
Updated: Oct 10, 2025
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for
Karthik Lingineni1, Varun Aggarwal2, Juan Francisco Morales1
1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Abstract:
Early clinical trials of therapies to treat Duchenne muscular dystrophy (DMD), a fatal genetic X-linked pediatric disease, have been designed based on the limited understanding of natural disease progression and variability in clinical measures over different stages of the continuum of the disease. The objective was to inform the design of DMD clinical trials by developing a disease progression model-based clinical trial simulation (CTS) platform based on measures commonly used in DMD trials. Data were integrated from past studies through the Duchenne Regulatory Science Consortium founded by the Critical Path Institute (15 clinical trials and studies, 1505 subjects, 27,252 observations). Using a nonlinear mixed-effects modeling approach, longitudinal dynamics of five measures were modeled (NorthStar Ambulatory Assessment, forced vital capacity, and the velocities of the following three timed functional tests: time to stand from supine, time to climb 4 stairs, and 10 meter walk-run time). The models were validated on external data sets and captured longitudinal changes in the five measures well, including both early disease when function improves as a result of growth and development and the decline in function in later stages. The models can be used in the CTS platform to perform trial simulations to optimize the selection of inclusion/exclusion criteria, selection of measures, and other trial parameters. The data sets and models have been reviewed by the US Food and Drug Administration and the European Medicines Agency; have been accepted into the Fit-for-Purpose and Qualification for Novel Methodologies pathways, respectively; and will be submitted for potential endorsement by both agencies.
Insights
This study developed a clinical trial simulation platform for Duchenne muscular dystrophy (DMD) by modeling disease progression. The platform aids in optimizing clinical trial designs for this pediatric genetic disease.
Area of Science:
- Biomedical Engineering
- Clinical Pharmacology
- Genetics
Background:
- Duchenne muscular dystrophy (DMD) is a fatal pediatric genetic disease with complex progression.
- Previous clinical trials for DMD faced challenges due to limited understanding of disease variability.
Purpose of the Study:
- To develop a disease progression model-based clinical trial simulation (CTS) platform for Duchenne muscular dystrophy.
- To inform and optimize the design of future DMD clinical trials.
Main Methods:
- Integrated data from 15 clinical trials and studies involving 1505 subjects.
- Utilized nonlinear mixed-effects modeling to analyze longitudinal data of five key functional measures.
- Validated models on external datasets to ensure accuracy across disease stages.
Main Results:
- Successfully modeled the longitudinal dynamics of NorthStar Ambulatory Assessment, forced vital capacity, and three timed functional tests.
- Models accurately captured disease progression, including functional improvements in early stages and decline in later stages.
- Validated models demonstrated robust performance on external datasets.
Conclusions:
- The developed CTS platform provides a valuable tool for optimizing DMD clinical trial parameters.
- Models support informed decision-making regarding inclusion/exclusion criteria and outcome measures.
- Regulatory agencies (FDA, EMA) have reviewed and accepted the data and models for novel methodology pathways.
